David T. Teachey

Children's Hospital of Philadelphia — United States

Medicine · Health Sciences

70h-index28.1kcitations611works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Lymphoblastic Leukemia research(331), CAR-T cell therapy research(112), Chronic Lymphocytic Leukemia Research(77), Chronic Myeloid Leukemia Treatments(71), Immune Cell Function and Interaction(62)

Publications610 total

CCR4 expression defines a targetable subset of T-cell acute lymphoblastic leukemia
Blood Advances·2026Open Access
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies
Blood·2026· 1 cited
μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia
Med·2026
A new sUSPect in T-ALL risk stratification
Blood Advances·2025Open Access
Widespread remodeling of the RNA editome underlies transcriptional and clinical heterogeneity in pediatric acute lymphoblastic leukemia
2025Open Access
The challenge of deintensifying chemotherapy for children and adolescents with B-ALL in the immunotherapy era
Hematology·2025Open Access
Supplementary Table 1 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
2025Open Access
Supplementary figures 1-9 from Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia
2025Open Access
Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia
Nature Communications·2025Open Access
A non-canonical lymphoblast in refractory childhood T-cell leukaemia
Nature Communications·2025Open Access
HEM-ismart: An international proof-of-concept therapeutic stratification trial of molecular anomalies in relapsed or refractory hematological malignancies in children
Blood·2025Open Access
Clinical characteristics and outcomes of children with T-cell acute lymphoblastic leukemia harboring ABL-class fusions: A report from the ponte di legno consortium
Blood·2025Open Access
Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731
Blood·2025Open Access
Inadequate social support and household material hardship among children with pediatric acute lymphoblastic leukemia: A report from the Children's oncology group Trial AALL1731
Blood·2025Open Access
Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children's oncology group
Blood·2025Open Access
Outcomes in children and adolescents with down syndrome and B-lymphoblastic leukemia: A report from Children's oncology group study AALL1731
Blood·2025Open Access
Factors associated with central nervous system relapse after b-acute lymphoblastic leukemia: A Children's oncology group report
Blood·2025Open Access
Immunoglobulin variable gene diversity reflects distinct metabolic/signaling states and impacts measurable residual disease monitoring and clinical outcome in B cell acute lymphoblastic leukemia
Blood·2025
National landscape of real-world pediatric blinatumomab care delivery in the United States: A report from the Children's Oncology Group
Blood·2025
Tallforest: Multi-omic classifier for T-lineage acute lymphoblastic leukemia
Blood·2025· 2 citedOpen Access
page 1 of 31Next →

Frequent Co-authors

Stephan A. Grupp(31), Shannon L. Maude(18), David M. Barrett(17), Carl H. June(10), Richard Aplenc(9), Simon F. Lacey(9), Alix E. Seif(8), Susan R. Rheingold(7), Bruce L. Levine(7), David L. Porter(7), Colleen Callahan(7), Mignon L. Loh(7), Stephen P. Hunger(7), Noelle V. Frey(6), Pamela A. Shaw(6), J. Joseph Melenhorst(6), Julie C. Fitzgerald(6), Tiffaney L. Vincent(6), Elizabeth A. Raetz(5), Sarah K. Tasian(5)